0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Accelerated sarcopenia precedes learning and memory impairments in the P301S mouse model of tauopathies and Alzheimer's disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Alzheimer's disease (AD) impairs cognitive functions and peripheral systems, including skeletal muscles. The PS19 mouse, expressing the human tau P301S mutation, shows cognitive and muscular pathologies, reflecting the central and peripheral atrophy seen in AD.

          Methods

          We analysed skeletal muscle morphology and neuromuscular junction (NMJ) through immunohistochemistry and advanced image quantification. A factorial Analysis of Variance assessed muscle weight, NCAM expression, NMJ, myofibre type distribution, cross‐sectional areas, expression of single or multiple myosin heavy‐chain isoforms, and myofibre grouping in PS19 and wild type (WT) mice over their lifespan (1–12 months).

          Results

          Significant weight differences in extensor digitorum longus (EDL) and soleus muscles between WT and PS19 mice were noted by 7–8 months. For EDL muscle in females, WT weighed 0.0113 ± 0.0005 compared with PS19's 0.0071 ± 0.0008 ( P < 0.05), and in males, WT was 0.0137 ± 0.0001 versus PS19's 0.0069 ± 0.0006 ( P < 0.005). Similarly, soleus muscle showed significant differences; females (WT: 0.0084 ± 0.0004; PS19: 0.0057 ± 0.0005, P < 0.005) and males (WT: 0.0088 ± 0.0003; PS19: 0.0047 ± 0.0004, P < 0.0001). Analysis of the NMJ in PS19 mice revealed a marked reduction in myofibre innervation at 5 months, with further decline by 10 months. NMJ pre‐terminals in PS19 mice became shorter and simpler by 5 months, showing a steep decline by 10 months. Genotype and age strongly influenced muscle NCAM immunoreactivity, denoting denervation as early as 5–6 months in EDL muscle Type II fibres, with earlier effects in soleus muscle Type I and II fibres at 3–4 months. Muscle denervation and subsequent myofibre atrophy were linked to a reduction in Type IIB fibres in the EDL muscle and Type IIA fibres in the soleus muscle, accompanied by an increase in hybrid fibres. The EDL muscle showed Type IIB fibre atrophy with WT females at 1505 ± 110 μm 2 versus PS19's 1208 ± 94 μm 2, and WT males at 1731 ± 185 μm 2 versus PS19's 1227 ± 116 μm 2. Similarly, the soleus muscle demonstrated Type IIA fibre atrophy from 5 to 6 months, with WT females at 1194 ± 52 μm 2 versus PS19's 858 ± 62 μm 2, and WT males at 1257 ± 43 μm 2 versus PS19's 1030 ± 55 μm 2. Atrophy also affected Type IIX, I + IIA, and IIA + IIX fibres in both muscles. The timeline for both myofibre and overall muscle atrophy in PS19 mice was consistent, indicating a simultaneous decline.

          Conclusions

          Progressive and accelerated neurogenic sarcopenia may precede and potentially predict cognitive deficits observed in AD.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

          Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity. Copyright 2010 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

            Filamentous tau inclusions are hallmarks of Alzheimer's disease (AD) and related tauopathies, but earlier pathologies may herald disease onset. To investigate this, we studied wild-type and P301S mutant human tau transgenic (Tg) mice. Filamentous tau lesions developed in P301S Tg mice at 6 months of age, and progressively accumulated in association with striking neuron loss as well as hippocampal and entorhinal cortical atrophy by 9-12 months of age. Remarkably, hippocampal synapse loss and impaired synaptic function were detected in 3 month old P301S Tg mice before fibrillary tau tangles emerged. Prominent microglial activation also preceded tangle formation. Importantly, immunosuppression of young P301S Tg mice with FK506 attenuated tau pathology and increased lifespan, thereby linking neuroinflammation to early progression of tauopathies. Thus, hippocampal synaptic pathology and microgliosis may be the earliest manifestations of neurodegenerative tauopathies, and abrogation of tau-induced microglial activation could retard progression of these disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention

              More than 25 million people in the world today are affected by dementia, most suffering from Alzheimer's disease. In both developed and developing nations, Alzheimer's disease has had tremendous impact on the affected individuals, caregivers, and society. The etiological factors, other than older age and genetic susceptibility, remain to be determined. Nevertheless, increasing evidence strongly points to the potential risk roles of vascular risk factors and disorders (eg, cigarette smoking, midlife high blood pressure and obesity, diabetes, and cerebrovascular lesions) and the possible beneficial roles of psychosocial factors (eg, high education, active social engagement, physical exercise, and mentally stimulating activity) in the pathogenetic process and clinical manifestation of the dementing disorders. The long-term multidomain interventions toward the optimal control of multiple vascular risk factors and the maintenance of socially integrated lifestyles and mentally stimulating activities are expected to reduce the risk or postpone the clinical onset of dementia, including Alzheimer's disease.
                Bookmark

                Author and article information

                Contributors
                odelbono@wakehealth.edu
                Journal
                J Cachexia Sarcopenia Muscle
                J Cachexia Sarcopenia Muscle
                10.1007/13539.2190-6009
                JCSM
                Journal of Cachexia, Sarcopenia and Muscle
                John Wiley and Sons Inc. (Hoboken )
                2190-5991
                2190-6009
                22 April 2024
                August 2024
                : 15
                : 4 ( doiID: 10.1002/jcsm.v15.4 )
                : 1358-1375
                Affiliations
                [ 1 ] Department of Internal Medicine, Sections on Gerontology and Geriatric Medicine Wake Forest University School of Medicine Winston‐Salem NC USA
                Author notes
                [*] [* ] Correspondence to: Osvaldo Delbono, Department of Internal Medicine, Section of Gerontology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston‐Salem, NC 27157, USA. Email: odelbono@ 123456wakehealth.edu

                Author information
                https://orcid.org/0000-0002-1613-8202
                Article
                JCSM13482 JCSM-D-23-01001
                10.1002/jcsm.13482
                11294019
                38646816
                72e1cdfd-2e21-4eb8-b0bb-335100aa1b55
                © 2024 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 27 February 2024
                : 21 November 2023
                : 10 March 2024
                Page count
                Figures: 8, Tables: 2, Pages: 18, Words: 6803
                Funding
                Funded by: National Institutes of Health , doi 10.13039/100000002;
                Award ID: R01AG071545
                Award ID: R01AG80586
                Categories
                Original Article
                Original Article
                Custom metadata
                2.0
                August 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.6 mode:remove_FC converted:01.08.2024

                Orthopedics
                alzheimer's disease,denervation,p301s tau mutation,ps19 mouse line,sarcopenia,skeletal muscle,tauopathies

                Comments

                Comment on this article